Creating Stem Cell Models of Inherited Heart Rhythm Disorders
Collects blood or skin samples from patients with inherited heart rhythm disorders and healthy volunteers.
Plain-language title generated from the registry record
Registry title: Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias
Key facts
- Where
- Baltimore, United StatesSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with an inherited heart rhythm problem, and their family members. Healthy adult controls also appear in the record. Blood or skin samples are used to make stem cell models of heart disease.
- Age
- 18 to 85 years
- Sex
- All sexes can join.
- Disease stage
- Inherited heart rhythm problems: long QT syndrome, Brugada syndrome, CPVT or early repolarization syndrome.
- Biomarker or test result
- Patients must have had genetic testing done for medical reasons.
Main reasons for not taking part
- Under 18 years of age
- Over 85 years of age
- Pregnant women
- Illnesses that limit life
- Weakened immune system
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT02413450, who can take part
Where in United States
- Johns Hopkins Medical InstituteBaltimore, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Johns Hopkins University
- Trial code
- NCT02413450
- Record updated
- 16 January 2026
- Original description
Human induced pluripotent stem cells (hiPSCs) have driven a paradigm shift in the modeling of human disease; the ability to reprogram patient-specific cells holds the promise of an enhanced understanding of disease mechanisms and phenotypic variability, with applications in personalized predictive pharmacology/toxicology, cell therapy and regenerative medicine. This research will collect blood or skin biopsies from patients and healthy controls for the purpose of generating cell and tissue models of Mendelian heritable forms of heart disease focusing on cardiomyopathies, channelopathies and neuromuscular diseases. Cardiomyocytes derived from hiPSCs will provide a ready source of disease specific cells to study pathogenesis and therapeutics.Read full original descriptionShow less
Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias (Long QT Syndrome, Brugada Syndrome, CPVT and Early Repolarization Syndrome)
Human induced pluripotent stem cells (hiPSCs) have driven a paradigm shift in the modeling of human disease; the ability to reprogram patient-specific cells holds the promise of an enhanced understanding of disease mechanisms and phenotypic variability, with applications in personalized predictive pharmacology/toxicology, cell therapy and regenerative medicine. This research will collect blood or skin biopsies from patients and healthy controls for the purpose of generating cell and tissue models of Mendelian heritable forms of heart disease focusing on cardiomyopathies, channelopathies and neuromuscular diseases. Cardiomyocytes derived from hiPSCs will provide a ready source of disease specific cells to study pathogenesis and therapeutics.
Inclusion: All patients and family members 18 years of age or older with inherited cardiac arrhythmias including LQTS, Brugada Syndrome (BrS), cathecholaminergic polymorphic ventricular tachycardia (CPVT) or early repolarization syndrome (ERS) are eligible for enrollment; All enrolled patients will have undergone clinically indicated genetic testing.
Exclusion: Age <18 years; >85 years; pregnant women; life-limiting co-morbidities; immunocompromise.